EASI Revenue and Competitors
Estimated Revenue & Valuation
- EASI's estimated annual revenue is currently $199.9M per year.
- EASI's estimated revenue per employee is $240,800
Employee Data
- EASI has 830 Employees.
- EASI grew their employee count by 0% last year.
EASI's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Business Development | Reveal Email/Phone |
2 | Director - Global Practices | Reveal Email/Phone |
3 | Program Manager | Reveal Email/Phone |
4 | Engineering Manager | Reveal Email/Phone |
5 | Project Manager | Reveal Email/Phone |
6 | Practice Manager | Reveal Email/Phone |
7 | Program Manager | Reveal Email/Phone |
8 | Sr. Manager | Reveal Email/Phone |
9 | Program Manager | Reveal Email/Phone |
10 | Project Manager Field Svc | Reveal Email/Phone |
EASI Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $199.9M | 830 | 0% | N/A | N/A |
#2 | $55.8M | 295 | 4% | N/A | N/A |
#3 | $6.3M | 46 | 2% | N/A | N/A |
#4 | $4.1M | 30 | -12% | N/A | N/A |
#5 | $8.5M | 55 | 10% | N/A | N/A |
#6 | $253.3M | 1052 | 89% | N/A | N/A |
#7 | $9.6M | 62 | -7% | N/A | N/A |
#8 | $5.8M | 42 | 0% | N/A | N/A |
#9 | $2.5M | 21 | 17% | N/A | N/A |
What Is EASI?
Business Services
keywords:N/A
N/A
Total Funding
830
Number of Employees
$199.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
EASI News
2022-04-20 - Global Cardiac Holter Monitor Market Analysis/Forecasts 2022-2027: Industry
Trends, Share, Growth, Insights, Impact of COVID-19, Company Analysis -
ResearchAndMarkets.com
Five EASI electrodes collect three channels of derived 12-Lead ECG, allowing for quick access to high-quality patient data and extending the...
2022-04-19 - Global Virgin Human Hair Market 2022 Major Growth and Top ...
Rebecca; Great Lengths; Hair Dreams; Easi Hair; Balmain; Donna Bella; Cinderella; Socap; Anhui Jinruixiang; Ruimei; Evergreen Products Group; Hairlocs...
2022-04-06 - LEO Pharma Presents New Interim Long-Term Efficacy Data for Adbry
(tralokinumab-ldrm) in Moderate-to-Severe Atopic Dermatitis at the 2022 RAD
Conference
In patients who completed 3 years of treatment with Adbry, the median Eczema Area and Severity Index (EASI) score improved by 93% (2.0 at 3...
Other Companies in Severn
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $475.3M | 1035 | 5% | N/A |
#2 | $75M | 1351 | 10% | N/A |
#3 | $564.7M | 1769 | 6% | N/A |
#4 | $472.8M | 2814 | -5% | N/A |
#5 | $551.4M | 3282 | 7% | N/A |